Literature DB >> 23940096

The role of metabolic imaging in radiation therapy of prostate cancer.

V Y Zhang1, A Westphalen, L Delos Santos, Z L Tabatabai, K Shinohara, D B Vigneron, J Kurhanewicz.   

Abstract

The goal of this study was to correlate prostatic metabolite concentrations from snap-frozen patient biopsies of recurrent cancer after failed radiation therapy with histopathological findings, including Ki-67 immunohistochemistry and pathologic grade, in order to identify quantitative metabolic biomarkers that predict for residual aggressive versus indolent cancer. A total of 124 snap-frozen transrectal ultrasound (TRUS)-guided biopsies were acquired from 47 men with untreated prostate cancer and from 39 men with a rising prostate-specific antigen and recurrent prostate cancer following radiation therapy. Biopsy tissues with Ki-67 labeling index ≤ 5% were classified as indolent cancer, while biopsy tissues with Ki-67 labeling index > 5% were classified as aggressive cancer. The majority (15 out of 17) of cancers classified as aggressive had a primary Gleason 4 pattern (Gleason score ≥ 4 + 3). The concentrations of choline-containing phospholipid metabolites (PC, GPC, and free Cho) and lactate were significantly elevated in recurrent cancer relative to surrounding benign tissues. There was also a significant increase in [PC] and reduction in [GPC] between untreated and irradiated prostate cancer biopsies. The concentration of the choline-containing phospholipid metabolites was significantly higher in recurrent aggressive (≈ twofold) than in recurrent indolent cancer biopsies, and the receiver operating characteristic (ROC) curve analysis of total choline to creatine ratio (tCho/Cr) demonstrated an accuracy of 95% (confidence interval = 0.88-1.00) for predicting aggressive recurrent disease. The tCho/Cr was significantly higher for identifying recurrent aggressive versus indolent cancer (tCho/Cr = 2.4 ± 0.4 versus 1.5 ± 0.2), suggesting that use of a higher threshold tCho/Cr ratio in future in vivo (1)H MRSI studies could improve the selection and therapeutic planning for patients who would benefit most from salvage focal therapy after failed radiation therapy.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Gleason score; HR-MAS; Ki-67; MR spectroscopy; pathologic grade; phospholipid metabolism; prostate cancer; radiation therapy

Mesh:

Substances:

Year:  2013        PMID: 23940096      PMCID: PMC3864570          DOI: 10.1002/nbm.3007

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  74 in total

1.  Ki-67 expression in early prostate cancer and associated pathological lesions.

Authors:  M R Feneley; M P Young; C Chinyama; R S Kirby; M C Parkinson
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

2.  Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Authors:  Mark G Swanson; Andrew S Zektzer; Z Laura Tabatabai; Jeffry Simko; Samson Jarso; Kayvan R Keshari; Lars Schmitt; Peter R Carroll; Katsuto Shinohara; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

3.  Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

Authors:  Brian Lee; Katsuto Shinohara; Vivian Weinberg; Alexander R Gottschalk; Jean Pouliot; Mack Roach; I-Chow Hsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-29       Impact factor: 7.038

4.  Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.

Authors:  Darko Pucar; Amita Shukla-Dave; Hedvig Hricak; Chaya S Moskowitz; Kentaro Kuroiwa; Semra Olgac; Lanie E Ebora; Peter T Scardino; Jason A Koutcher; Kristen L Zakian
Journal:  Radiology       Date:  2005-06-21       Impact factor: 11.105

5.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy.

Authors:  Antonio C Westphalen; John Kurhanewicz; Rui M G Cunha; I-Chow Hsu; John Kornak; Shoujun Zhao; Fergus V Coakley
Journal:  Int Braz J Urol       Date:  2009 Mar-Apr       Impact factor: 1.541

7.  High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.

Authors:  Siavash Jabbari; I-Chow Hsu; Jun Kawakami; Vivian K Weinberg; Joycelyn L Speight; Alexander R Gottschalk; Mack Roach; Katsuto Shinohara
Journal:  Brachytherapy       Date:  2009-05-09       Impact factor: 2.362

8.  Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging.

Authors:  Barby Pickett; Randall K Ten Haken; John Kurhanewicz; Aliya Qayyum; Katsuto Shinohara; Beverly Fein; Mack Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-01       Impact factor: 7.038

9.  Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Authors:  Patrick A Kupelian; Louis Potters; Deepak Khuntia; Jay P Ciezki; Chandana A Reddy; Alwyn M Reuther; Thomas P Carlson; Eric A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-01-01       Impact factor: 7.038

10.  Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer.

Authors:  Alexander S Parker; Michael G Heckman; Kevin J Wu; Julia E Crook; Tracy W Hilton; Thomas M Pisansky; Johnny R Bernard; Steven E Schild; Li Yan Khor; Elizabeth H Hammond; Alan Pollack; Steven J Buskirk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

View more
  5 in total

1.  Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model.

Authors:  Hecong Qin; Vickie Zhang; Robert A Bok; Romelyn Delos Santos; J Adam Cunha; I-Chow Hsu; Justin Delos Santos Bs; Jessie E Lee; Subramaniam Sukumar; Peder E Z Larson; Daniel B Vigneron; David M Wilson; Renuka Sriram; John Kurhanewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-04-25       Impact factor: 7.038

Review 2.  The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Authors:  Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-30       Impact factor: 7.038

3.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

Review 4.  Biomarkers for prostate cancer: present challenges and future opportunities.

Authors:  Pranav Sharma; Kamran Zargar-Shoshtari; Julio M Pow-Sang
Journal:  Future Sci OA       Date:  2015-12-17

5.  Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Authors:  Michael Deal; Florian Bardet; Paul-Michael Walker; Mathilde Funes de la Vega; Alexandre Cochet; Luc Cormier; Imad Bentellis; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.